Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria

K. Marth (Vienna, Austria), A. Renner (Vienna, Austria), K. Patocka (Vienna, Austria), W. Pohl (Vienna, Austria)

Source: International Congress 2018 – Notable Studies in Asthma
Session: Notable Studies in Asthma
Session type: Oral Presentation
Number: 3568
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Marth (Vienna, Austria), A. Renner (Vienna, Austria), K. Patocka (Vienna, Austria), W. Pohl (Vienna, Austria). Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria. 3568

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: